Kelly Financial Services LLC Alkermes Plc. Transaction History

Kelly Financial Services LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jul 17, 2024	SELL	$27.17 - $31.97 $2,717 - $3,197	-100 Closed	0 $0
Q3 2021 Jul 17, 2024	SELL	$23.37 - $32.13 $54,966 - $75,569	-2,352 Reduced 95.92%	100 $3.08 Million
Q2 2021 Jul 17, 2024	BUY	$18.78 - $25.15 $44,170 - $59,152	2,352 Added 2352.0%	2,452 $100,000
Q3 2019 Jul 17, 2024	SELL	$19.51 - $24.28 $468 - $582	-24 Reduced 19.35%	100 $1.95 Million
Q1 2019 Jul 17, 2024	BUY	$28.4 - $36.49 $3,521 - $4,524	124 New	124 $4.53 Million

358

180M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.12B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.